Sei Investments Co. increased its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 246.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,411 shares of the medical instruments supplier's stock after purchasing an additional 3,848 shares during the quarter. Sei Investments Co. owned approximately 0.10% of Mesa Laboratories worth $714,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Pacer Advisors Inc. boosted its holdings in shares of Mesa Laboratories by 4.3% during the fourth quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock worth $231,000 after purchasing an additional 73 shares during the period. Berry Wealth Group LP lifted its position in Mesa Laboratories by 5.3% in the 4th quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock worth $219,000 after buying an additional 83 shares in the last quarter. FMR LLC lifted its position in Mesa Laboratories by 34.1% in the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier's stock worth $51,000 after buying an additional 100 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Mesa Laboratories by 3.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,394 shares of the medical instruments supplier's stock valued at $448,000 after buying an additional 100 shares during the period. Finally, Amundi grew its holdings in shares of Mesa Laboratories by 81.6% during the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier's stock valued at $91,000 after acquiring an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company's stock.
Insider Transactions at Mesa Laboratories
In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the sale, the chief executive officer now owns 43,337 shares of the company's stock, valued at $5,369,887.67. The trade was a 32.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.40% of the stock is currently owned by company insiders.
Mesa Laboratories Stock Up 4.3 %
Shares of NASDAQ MLAB traded up $4.71 during mid-day trading on Friday, reaching $114.57. The company had a trading volume of 35,186 shares, compared to its average volume of 38,788. The stock has a market capitalization of $622.57 million, a PE ratio of -2.48 and a beta of 0.92. Mesa Laboratories, Inc. has a twelve month low of $83.68 and a twelve month high of $155.12. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.53 and a current ratio of 0.71. The stock's 50 day moving average is $130.23 and its 200-day moving average is $128.21.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. As a group, equities analysts anticipate that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.
Mesa Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.56%. The ex-dividend date is Friday, May 30th. Mesa Laboratories's dividend payout ratio is -1.38%.
About Mesa Laboratories
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
See Also
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
